PTGS2 and colorectal cancer: To test whether cetuximab plus inhibition of COX-2 is an effective approach for treating COX-2-overexpressing colorectal cancer cells with naturally occurring resistance to cetuximab, we performed a proof-of-concept study to examine the effect of combination treatment with cetuximab and a COX-2 inhibitor in Caco2 cells.